-
The FDA has approved Pfizer's eplerenone (Inspra) for the treatment of congestive heart failure (CHF) in patients who have sustained a myocardial infarction.
-
-
Sulfonamide Antibiotics and Sulfonamide Nonantibiotics; Autoantibodies Before Onset of SLE; Prevention of VTE with Ximelagatran
-
Two injectable biologic therapies, etanercept and efalizumab, have been shown to be highly effective in treating psoriasis. Etanercept has been used in rheumatoid arthritis since 1998, and efalizumab is a new agent in phase III trials. Psoriasis is a debilitating autoimmune illness, and these new therapies, while expensive, will be a welcome addition for patients suffering from a severe form of this disease.
-
The FDA has approved tadalafil, the third phosphodiesterase type 5 inhibitor (PDE5) for the treatment of erectile dysfunction.
-
A majority of gastric fundic polyps are benign. Their presence in unscreened individuals older than 50 might warrant colonoscopy.
-
The study found that high-intensity warfarin therapy was not necessary for the prevention of recurrent thrombosis in the APA syndrome.
-
A consensus panel updates recent understanding about the causes and treatment in common neuropathic pain problems.
-
A high saturated-fat and no-starch diet resulted in modest weight loss without negative effects on serum lipid levels; weight loss can be continued for up to a year with such a diet.
-
Thomson American Health Consultants is happy to announce that we are opening up our Primary Care Reports author process to our readers. A biweekly newsletter with approximately 5000 readers, each issue is a fully referenced, peer-reviewed monograph.